LILRB1 and neoplasm: Specifically, inhibition of phagocytosis is driven by interaction between LILRB1 on macrophages and the MHC class I‐associated β2M subunit expressed by tumor cells,30 highlighting the potential universality of this innate checkpoint as a means for tumor immune evasion in cancer patients regardless of their HLA haplotype.